The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
February 1st 2025
Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Rise in Pediatric Diabetes Cases Continued Through Year 2 of COVID-19 Pandemic
July 19th 2023An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.
ASA Urges Withholding GLP-1 RA Therapy Prior to Elective Procedures
July 14th 2023With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.
Study Finds Prescribing Fruits and Vegetables Could Reduce Future Healthcare Spending by $40 Billion
July 14th 2023A microsimulation model leveraging data from NHANES suggests monthly prescriptions of fruits and vegetables to people with diabetes and food insecurity could prevent nearly 300,000 cardiovascular disease events over a 25-year period.
Tandem Mobi Insulin Pump, Billed as World's Smallest Insulin Pump, Receives FDA Clearance
July 12th 2023Announced by Tandem Diabetes Care on July 11, 2023, the Tandem Mobi insulin pump is billed as the world's smallest insulin pump, at less than half the size of the t:slim X2 pump and able to fit in a coin pocket.
Beyond Glucose Control - The Expanding Role of Incretins in Diabetes and Obesity Management
July 11th 2023In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.
Beyond Glucose Control: The Expanding Role of Incretins in Diabetes and Obesity Management
July 11th 2023In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.
Diabetes Dialogue: Latest News in Insulin Delivery, with Gary Scheiner, MS
July 11th 2023Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.
Expanded CGM Access Could Usher in New Era of Diabetes Management
July 10th 2023Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.
Diabetes Dialogue: Embracing Diabetes Tech and Social Media as a Clinician, with David Ahn, MD
July 7th 2023David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.
Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric
July 6th 2023Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.
Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D
July 2nd 2023After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.